TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 17-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial Of Pregabalin For The Treatment Of Chronic Central Neuropathic Pain After Spinal Cord Injury
Brief Summary: The purpose of this study is to evaluate if pregabalin relieves nerve pain associated with spinal cord injury compared to placebo (pill that contains no active medicine). This study will also evaluate the safety of pregabalin in this patient population.


Options:
A: Arm Label: Imipramine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Imipramine | Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pregabalin | Arm Label: Imipramine plus pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Imipramine, pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Imipramine; Assigned to Arm(s): Imipramine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: Imipramine, pregabalin; Assigned to Arm(s): Imipramine plus pregabalin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: matched placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): matched placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): pregabalin
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pregabalin; Type: OTHER; Interventions: Drug: Pregabalin | Arm Label: GEn 1200mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 1200mg/day | Arm Label: GEn 2400mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 2400mg/day | Arm Label: GEn 3600mg/day; Type: EXPERIMENTAL; Interventions: Drug: GEn 3600mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: GEn 1200mg/day; Assigned to Arm(s): GEn 1200mg/day | Intervention Type: DRUG; Name: GEn 2400mg/day; Assigned to Arm(s): GEn 2400mg/day | Intervention Type: DRUG; Name: GEn 3600mg/day; Assigned to Arm(s): GEn 3600mg/day | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Two Resurfacing Prostheses in the Treatment of Osteoarthritis of the Shoulder A Prospective, Randomized Migration and Bone Density Study
Brief Summary: The purpose of this study is to determine whether there is a difference between the result of treatment of shoulder osteoarthritis with two different shoulder prostheses.


Options:
A: Arm Label: Anatomic TSA using SOC Instrumentation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Anatomic Total Shoulder Arthroplasty | Arm Label: Anatomic TSA Using IRI Instrumentation; Type: EXPERIMENTAL; Interventions: Device: Anatomic TSA using IRI Instrumentation, Procedure: Anatomic Total Shoulder Arthroplasty | Intervention Type: DEVICE; Name: Anatomic TSA using IRI Instrumentation; Assigned to Arm(s): Anatomic TSA Using IRI Instrumentation | Intervention Type: PROCEDURE; Name: Anatomic Total Shoulder Arthroplasty; Assigned to Arm(s): Anatomic TSA Using IRI Instrumentation, Anatomic TSA using SOC Instrumentation
B: Intervention Type: PROCEDURE; Name: Cemented Humeral Stem; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Uncemented Humeral Stem; Assigned to Arm(s): N/A
C: Arm Label: 0 degrees humeral component version; Type: EXPERIMENTAL; Interventions: Device: 0 degrees humeral component version | Arm Label: 30 degrees humeral component retroversion; Type: EXPERIMENTAL; Interventions: Device: 30 degrees humeral component retroversion | Intervention Type: DEVICE; Name: 0 degrees humeral component version; Assigned to Arm(s): 0 degrees humeral component version | Intervention Type: DEVICE; Name: 30 degrees humeral component retroversion; Assigned to Arm(s): 30 degrees humeral component retroversion
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Copeland or Global CAP resurfacing prosthesis | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Copeland or Global CAP resurfacing prosthesis | Intervention Type: PROCEDURE; Name: Copeland or Global CAP resurfacing prosthesis; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial to Assess the Utility of Empirical Anti-Arrhythmic Drug Therapy to Prevent Atrial Arrhythmia During the 6 Weeks Following Pulmonary Vein Isolation to Treat Paroxysmal Atrial Fibrillation
Brief Summary: The purpose of this study is to examine the overall effectiveness of anti-arrhythmic medicines (to control heart rhythm) prescribed after an ablation procedure for atrial fibrillation.


Options:
A: Arm Label: NAVISTAR® THERMOCOOL® Catheter; Type: EXPERIMENTAL; Interventions: Device: NAVISTAR® THERMOCOOL® Catheter | Arm Label: Antiarrhythmic drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: DEVICE; Name: NAVISTAR® THERMOCOOL® Catheter; Assigned to Arm(s): NAVISTAR® THERMOCOOL® Catheter | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Antiarrhythmic drug
B: Arm Label: Dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Additional ablation until elimination of dormant conduction, Procedure: No additional ablation | Arm Label: No dormant PV conduction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Registry group, Procedure: Usual medical care | Intervention Type: PROCEDURE; Name: Additional ablation until elimination of dormant conduction; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: No additional ablation; Assigned to Arm(s): Dormant PV conduction | Intervention Type: PROCEDURE; Name: Registry group; Assigned to Arm(s): No dormant PV conduction | Intervention Type: PROCEDURE; Name: Usual medical care; Assigned to Arm(s): No dormant PV conduction
C: Arm Label: Atrial Fibrillation Ablation; Type: EXPERIMENTAL; Interventions: Procedure: Atrial fibrillation ablation | Arm Label: Drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Antiarrhythmic drug | Intervention Type: PROCEDURE; Name: Atrial fibrillation ablation; Assigned to Arm(s): Atrial Fibrillation Ablation | Intervention Type: DRUG; Name: Antiarrhythmic drug; Assigned to Arm(s): Drug therapy
D: Arm Label: AAD:YES; Type: OTHER; Interventions: Drug: propafenone; flecainide; sotalol; dofetilide, Device: Radiofrequency catheter ablation | Arm Label: AAD:NO; Type: OTHER; Interventions: Device: Radiofrequency catheter ablation | Intervention Type: DRUG; Name: propafenone; flecainide; sotalol; dofetilide; Assigned to Arm(s): AAD:YES | Intervention Type: DEVICE; Name: Radiofrequency catheter ablation; Assigned to Arm(s): AAD:NO, AAD:YES

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study
Brief Summary: The purpose of this study is to compare the effects of self-help materials for smoking cessation and self-help materials for smoking cessation plus prize-based contingency management (CM), in which prize incentives are available for breath and saliva samples that indicate smoking abstinence, in substance abuse treatment patients who want to quit smoking.


Options:
A: Arm Label: Traditional Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Traditional Contingency Management | Arm Label: Early Enhanced Contingency Management; Type: EXPERIMENTAL; Interventions: Behavioral: Early Enhanced Contingency Management | Arm Label: Standard Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Treatment | Intervention Type: BEHAVIORAL; Name: Standard Treatment; Assigned to Arm(s): Standard Treatment | Intervention Type: BEHAVIORAL; Name: Traditional Contingency Management; Assigned to Arm(s): Traditional Contingency Management | Intervention Type: BEHAVIORAL; Name: Early Enhanced Contingency Management; Assigned to Arm(s): Early Enhanced Contingency Management
B: Arm Label: Experimental group:financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentive | Arm Label: Control group:no financial intervention; Type: OTHER; Interventions: Other: No financial incentive | Intervention Type: BEHAVIORAL; Name: Financial incentive; Assigned to Arm(s): Experimental group:financial incentives | Intervention Type: OTHER; Name: No financial incentive; Assigned to Arm(s): Control group:no financial intervention
C: Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Arm Label: Lung Age; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age | Arm Label: Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management | Arm Label: Lung age + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lung age + Contingency Management | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care | Intervention Type: BEHAVIORAL; Name: Lung age; Assigned to Arm(s): Lung Age | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Contingency Management | Intervention Type: BEHAVIORAL; Name: Lung age + Contingency Management; Assigned to Arm(s): Lung age + Contingency Management
D: Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine 60 to 120 mg Versus Placebo in the Treatment of Patients With Osteoarthritis Knee Pain
Brief Summary: The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluating a Low-Literacy Discharge Medication Education Tool
Brief Summary: Recent studies have demonstrated that patients sub-optimally understand hospital discharge medication instructions Health literacy has been shown to be an important factor in patient understanding of medical information , and following medication instructions.

The primary aim of this project is to test the efficacy of a low-literacy discharge medication education tool on medication adherence, and patient knowledge and understanding of inpatient discharge medications, in a low-income population with low health literacy levels. This evaluation is a prospective trial with patients randomly assigned to either receiving this tool or receiving the current standard of care. Given the complexity of the discharge medication regimen for the conditions of congestive heart failure (CHF) and coronary artery disease (CAD), and the proven effectiveness of these medications in the post discharge period, this trial will focus on the subpopulation of patients hospitalized with these two conditions.


Options:
A: Arm Label: AF Clinic; Type: EXPERIMENTAL; Interventions: Other: AF Clinic | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Care as Usual | Intervention Type: OTHER; Name: AF Clinic; Assigned to Arm(s): AF Clinic | Intervention Type: OTHER; Name: Care as Usual; Assigned to Arm(s): Care as Usual
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Medication Education Tool | Intervention Type: OTHER; Name: Medication Education Tool; Assigned to Arm(s): 2
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: SBAR | Intervention Type: OTHER; Name: SBAR; Assigned to Arm(s): 2
D: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Investigate Safety and Efficacy of Tibolone (Org OD14) in Women With Climacteric Symptoms and a History of Breast Cancer
Brief Summary: Postmenopausal women with a history of breast cancer often suffer from climacteric symptoms such as hot flushes and sweating episodes. Conventional hormone therapy is not allowed in such patients because there are indications that hormones may cause breast cancer to recur.

Tibolone is a steroid with estrogenic, progestogenic and androgenic activity and is registered for treatment of climacteric complaints. Tibolone has a pharmacologic and clinical profile that is different from conventional hormones. In contrast to conventional hormones, tibolone does not increase breast density and causes less breast pain.

The LIBERATE study is a study in which the safety and efficacy of tibolone has been investigated in postmenopausal women that have been treated for breast cancer.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bazedoxifene/Conjugate Estrogens (CE) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Raloxifene | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bazedoxifene/Conjugate Estrogens (CE); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Raloxifene; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): C
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: SCE-B, Drug: Placebo | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SCE-B; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3
C: Arm Label: Tibolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: tibolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tibolone; Assigned to Arm(s): Tibolone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment 1; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 2; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 3; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Treatment 4; Type: EXPERIMENTAL; Interventions: Drug: Estradiol, Drug: Progesterone, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Progesterone; Assigned to Arm(s): Treatment 1, Treatment 2, Treatment 3, Treatment 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Treatment 1, Treatment 2, Treatment 3, Treatment 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain
Brief Summary: The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition--Whether duloxetine once daily can help patients with Chronic Low Back Pain.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
C: Arm Label: Duloxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Duloxetine 120 mg; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 120 mg, Duloxetine 20 mg, Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China
Brief Summary: To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: ABT-894 | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: E; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): A | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): B | Intervention Type: DRUG; Name: ABT-894; Assigned to Arm(s): C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): D | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): E
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Duloxetine placebo, Drug: Methadone, Drug: Methadone placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Duloxetine placebo; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Methadone placebo; Assigned to Arm(s): 1, 2, 3, 4
D: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian "Never Smoker" Patients With Advanced Non-Small Cell Lung Cancer
Brief Summary: The purpose of this study is to compare the efficacy and safety of chemotherapy followed sequentially by gefitinib versus chemotherapy alone in the first line treatment of non-small cell lung cancer (NSCLC). This study will be conducted in Asian patients who are classified as 'never smoker' since it is suggested that these patients are more likely to respond favorably to treatment with gefitinib.


Options:
A: Intervention Type: DRUG; Name: gefitinib; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A
B: Arm Label: gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): gefitinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
C: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA
D: Arm Label: Pemetrexed/Cisplatin/Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Pemetrexed/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed/Cisplatin, Pemetrexed/Cisplatin/Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed/Cisplatin, Pemetrexed/Cisplatin/Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed/Cisplatin/Gefitinib

Answer: D